Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?
作者信息
Zheng Lei
机构信息
Departments of Oncology & Surgery, The Sidney Kimmel Cancer Center, & the Skip Viragh Center for Pancreatic Cancer Research & Clinical Care, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 Room 488, Baltimore, MD 21231, USA.
出版信息
Immunotherapy. 2014;6(10):1017-20. doi: 10.2217/imt.14.87.
Abstract
摘要
相似文献
1
Does vaccine-primed pancreatic cancer offer better candidates for immune-based therapies?
Immunotherapy. 2014;6(10):1017-20. doi: 10.2217/imt.14.87.
2
Immunologic approaches to the management of pancreatic cancer.
Cancer J. 2001 Jul-Aug;7(4):324-37.
3
Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.
Hum Vaccin Immunother. 2014;10(11):3354-68. doi: 10.4161/hv.34392.
4
Immunotherapy for pancreatic cancer: present and future.
Immunotherapy. 2017 Jun;9(7):607-616. doi: 10.2217/imt-2016-0142.
5
Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.
Cancer Immunol Res. 2014 Jul;2(7):616-31. doi: 10.1158/2326-6066.CIR-14-0027. Epub 2014 Jun 18.
6
Emerging trends in the immunotherapy of pancreatic cancer.
Cancer Lett. 2018 Mar 28;417:35-46. doi: 10.1016/j.canlet.2017.12.012. Epub 2017 Dec 12.
7
Advances in immunotherapy for pancreatic cancer: 2013.
JOP. 2013 Jul 10;14(4):347-53. doi: 10.6092/1590-8577/1646.
8
PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.
J Immunother. 2015 Jan;38(1):1-11. doi: 10.1097/CJI.0000000000000062.
9
Immunotherapy for pancreatic ductal adenocarcinoma.
J Surg Oncol. 2021 Mar;123(3):751-759. doi: 10.1002/jso.26312.
10
Immunotherapy synergizes with chemotherapy targeting pancreatic cancer.
Immunotherapy. 2012 Jan;4(1):5-7. doi: 10.2217/imt.11.150.
引用本文的文献
1
Association between Expression and Immune Dysregulation in Pancreatic Ductal Adenocarcinoma: Insights from Comprehensive Immune Profiling of Peripheral Blood Mononuclear Cells.
Cancers (Basel). 2023 Sep 19;15(18):4639. doi: 10.3390/cancers15184639.
2
Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects.
Chronic Dis Transl Med. 2020 Feb 11;6(1):6-17. doi: 10.1016/j.cdtm.2020.01.002. eCollection 2020 Mar.
3
IDO1 inhibition potentiates vaccine-induced immunity against pancreatic adenocarcinoma.
J Clin Invest. 2019 Apr 1;129(4):1742-1755. doi: 10.1172/JCI124077. Epub 2019 Mar 18.
4
Clinical evaluation of macrophages in cancer: role in treatment, modulation and challenges.
Cancer Immunol Immunother. 2017 Dec;66(12):1509-1527. doi: 10.1007/s00262-017-2065-0. Epub 2017 Sep 25.
5
Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors.
Cancer Biol Med. 2015 Sep;12(3):201-8. doi: 10.7497/j.issn.2095-3941.2015.0046.
本文引用的文献
1
PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors.
J Immunother. 2015 Jan;38(1):1-11. doi: 10.1097/CJI.0000000000000062.
2
Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation.
Cancer Immunol Res. 2014 Jul;2(7):616-31. doi: 10.1158/2326-6066.CIR-14-0027. Epub 2014 Jun 18.
3
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.
Clin Cancer Res. 2014 Oct 1;20(19):5064-74. doi: 10.1158/1078-0432.CCR-13-3271. Epub 2014 Apr 8.
4
Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.
Oncotarget. 2014 Feb 15;5(3):587-98. doi: 10.18632/oncotarget.1782.
5
Characteristics of tertiary lymphoid structures in primary cancers.
Oncoimmunology. 2013 Dec 1;2(12):e26836. doi: 10.4161/onci.26836. Epub 2013 Oct 22.
6
Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.
Oncotarget. 2013 Nov;4(11):2067-79. doi: 10.18632/oncotarget.1542.
7
Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.
J Immunother. 2013 Sep;36(7):382-9. doi: 10.1097/CJI.0b013e31829fb7a2.
8
Nivolumab plus ipilimumab in advanced melanoma.
N Engl J Med. 2013 Jul 11;369(2):122-33. doi: 10.1056/NEJMoa1302369. Epub 2013 Jun 2.
9
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.
N Engl J Med. 2013 Jul 11;369(2):134-44. doi: 10.1056/NEJMoa1305133. Epub 2013 Jun 2.
10
Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma.
Gastroenterology. 2013 Jun;144(6):1230-40. doi: 10.1053/j.gastro.2012.12.042.
Zotero 插件